Prostate Cancer, Version 3.2026

Prostate Cancer, Version 3.2026 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H. H., Cho, S. Y., D'amico, A., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Gupta, S., Ippolito, J. E., Karnes, J., Kishan, A., Kuettel, M. R., Lang, J. M., Lee, D., Lotan, T., Mcdonald, A., Morgan, T., Pessoa, R., Rais-Bahrami, S., Roach Iii, M., Robin, T., Rosenfeld, S., Scarpato, K. R., Shabsigh, A., Szmulewitz, R., Teply, B. A., Tward, J., Valicenti, R., Vanderweele, D., Wong, J., Kovach, E., Freedman-Cass, D. 2025; 23 (11): 469-493

Abstract

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). For patients with mCSPC, disease characteristics, such as whether metastases arose synchronously or metachronously and the degree of metastatic burden, impact therapy decisions, including how much treatment intensification is appropriate and when prostate-directed and/or metastasis-directed therapy should be considered. In the mCRPC setting, androgen deprivation therapy is continued with the sequential or concurrent addition of certain androgen receptor pathway inhibitors, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, biomarkers, the extent and location of metastases, symptoms, and potential side effects.

View details for DOI 10.6004/jnccn.2025.0052

View details for Web of Science ID 001622583200013

View details for PubMedID 41213253